CP-751,871 + Docetaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Non-Hematologic Malignancies
Conditions
Advanced Non-Hematologic Malignancies
Trial Timeline
Mar 1, 2005 → Feb 1, 2009
NCT ID
NCT01653158About CP-751,871 + Docetaxel
CP-751,871 + Docetaxel is a phase 1 stage product being developed by Pfizer for Advanced Non-Hematologic Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT01653158. Target conditions include Advanced Non-Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00678626 | Phase 2 | Withdrawn |
| NCT01653158 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Non-Hematologic Malignancies